Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

OBJECTIVE: To evaluate the efficacy and safety of PF‐06651600 (ritlecitinib), an irreversible inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, in comparison with placebo in patients with rheumatoid arthritis (RA). METHODS: An 8‐week, phase II, doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Michael F., Damjanov, Nemanja, Stamenkovic, Bojana, Radunovic, Goran, Kivitz, Alan, Cox, Lori, Manukyan, Zorayr, Banfield, Christopher, Saunders, Michael, Chandra, Deepa, Vincent, Michael S., Mancuso, Jessica, Peeva, Elena, Beebe, Jean S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589242/
https://www.ncbi.nlm.nih.gov/pubmed/32419304
http://dx.doi.org/10.1002/art.41316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589242/
https://www.ncbi.nlm.nih.gov/pubmed/32419304
http://dx.doi.org/10.1002/art.41316

Ejemplares similares